Loading
A drug that improves appetite and lean weight in cancer wasting is approved in Japan but almost nowhere else. Reviewing the existing evidence could widen access quickly.
Anamorelin, a ghrelin receptor agonist, is approved in Japan for cancer cachexia in several tumour types, having shown gains in lean body mass with inconsistent effects on handgrip strength in the ROMANA programme. Other regulators declined largely on the function endpoint. A reappraisal using pooled data with a qualified function endpoint, or a confirmatory pragmatic trial in a stratified population, could resolve the question.
Shares Definition and classification of cancer cachexia: an international consensus, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology.
Shares Definition and classification of cancer cachexia: an international consensus, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Pancreatic ductal adenocarcinoma.
Shares ROMANA 1 and ROMANA 2, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology.
Shares Definition and classification of cancer cachexia: an international consensus, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Cachexia, toxicity and the limits of the patient, Most of the world has almost no cancer care.
Shares Definition and classification of cancer cachexia: an international consensus, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Non-small-cell lung cancer.
Shares ROMANA 1 and ROMANA 2, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Exercise & lifestyle oncology, Gastric & gastro-oesophageal junction cancer.
Shares Definition and classification of cancer cachexia: an international consensus, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology.
Shares Cachexia, toxicity and the limits of the patient, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.